Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kurt W. Evans"'
Autor:
Turcin Saridogan, Argun Akcakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott, Bryce P. Kirby, Xiaofeng Zheng, Min Jin Ha, Huiqin Chen, Patrick K. S. Ng, Timothy P. DiPeri, Gordon B. Mills, Jordi Rodon Ahnert, Senthil Damodaran, Funda Meric-Bernstam
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as therapeutic targets. Futibatinib (TAS-120; Taiho) is a novel, selective, pan-FGFR inhib
Externí odkaz:
https://doaj.org/article/54d8ba5ed19745f68237d1d74ca99a08
Autor:
Ming Zhao, Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans, Fei Yang, Argun Akcakanat, Marco Roberto Estecio, Debu Tripathy, Ecaterina E. Dumbrava, Senthil Damodaran, Funda Meric-Bernstam
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-14 (2023)
Abstract TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression. In metaplastic breast cancers (MpBC), there is limited expression of TROP2
Externí odkaz:
https://doaj.org/article/153c2e942072429c8da59c33c6ea4273
Autor:
Seyed Pairawan, Argun Akcakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Rizvi, Vijaykumar Holla, Jing Wang, Kurt W. Evans, Ming Zhao, Naifa Busaidy, Bingliang Fang, Jack A. Roth, Ecaterina Ileana Dumbrava, Funda Meric-Bernstam
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-15 (2022)
Abstract Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-typ
Externí odkaz:
https://doaj.org/article/51b40b75a51c478a93d56c2bf88693c8
Autor:
Rozita Bagheri-Yarmand, Naifa L. Busaidy, Elena McBeath, Brian P. Danysh, Kurt W. Evans, Tyler J. Moss, Argun Akcakanat, Patrick K. S. Ng, Christina M. Knippler, Jalyn A. Golden, Michelle D. Williams, Asha S. Multani, Maria E. Cabanillas, Kenna R. Shaw, Funda Meric-Bernstam, Manisha H. Shah, Matthew D. Ringel, Marie Claude Hofmann
Publikováno v:
Cancers, Vol 13, Iss 19, p 4950 (2021)
BRAF-activating mutations are the most frequent driver mutations in papillary thyroid cancer (PTC). Targeted inhibitors such as dabrafenib have been used in advanced BRAF-mutated PTC; however, acquired resistance to the drug is common and little is k
Externí odkaz:
https://doaj.org/article/9dc7cfc458d04b738ddeef3983415062
Autor:
Natalia Paez Arango, Erkan Yuca, Ming Zhao, Kurt W. Evans, Stephen Scott, Charissa Kim, Ana Maria Gonzalez-Angulo, Filip Janku, Naoto T. Ueno, Debu Tripathy, Argun Akcakanat, Aung Naing, Funda Meric-Bernstam
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-10 (2017)
Abstract Background Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative breast cancer (TNBC), we sought to determine the antitumor effects of s
Externí odkaz:
https://doaj.org/article/aa1049178cee4907862f726c8c7667ec
Autor:
Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0151121 (2016)
Externí odkaz:
https://doaj.org/article/3f58caf117d4453f9c614ffcebd247ec
Autor:
Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0136851 (2015)
Breast cancer patients who are resistant to neoadjuvant chemotherapy (NeoCT) have a poor prognosis. There is a pressing need to develop in vivo models of chemo resistant tumors to test novel therapeutics. We hypothesized that patient-derived breast c
Externí odkaz:
https://doaj.org/article/7b19cd5ca69e48e9bcf7d70a6c6b420b